Tibet Weixinkang Medicine Co., Ltd. (603676.SS)
ValueMarkers Composite Index
82% below intrinsic value ($8)
Tibet Weixinkang Medicine Co., Ltd. (603676.SS) — VMCI valuation read
603676.SS screens at VMCI 66/100, a 16-point gap above the Healthcare sector median (50). For a mid-cap Tibet Weixinkang Medicine Co., Ltd. share, that placement says the multi-pillar composite is cheaper or higher quality than the typical peer on a like-for-like basis.
603676.SS has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.
**Investor frame.** Value: 603676.SS trades at 18.0x earnings, 0% above the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 8.0% trails the Healthcare median (10.0%) by 2.0pp, the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of 2.8x is the rate-sensitivity line to watch, which sets the rate-cycle exposure for Tibet Weixinkang Medicine Co., Ltd..
603676.SS rose 0.3% over the trailing 7 days, with a -23.1% read on a 30-day basis.
Tibet Weixinkang Medicine Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company's products include parenteral nutrition vitamins, electrolyte supplements, intravenous iron supplements, antibiotics, and medicine for digestive system and liver diseases. It also offers injection multivitamins, potassium magnesium aspartate for injection, iron sucrose injection, potassium aspartate injection, etc. The company was formerly known as Weixinkang Medicine Youxian Gongsi and changed its name to Tibet Weixinkang Medicine Co., Ltd. in 2015. Tibet Weixinkang Medicine Co., Ltd. was founded in 2006 and is based in Lhasa, China.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.